Albany, New York, May 30, 2017: Market Research Hub’s Pharmaceutical and Healthcare latest pipeline guide Chagas Disease – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Request Free Sample Report @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1070413
Chagas disease or American Trypanosomiasis is a vector-borne anthropozoonosis caused by the protozoan parasite Trypanosoma cruzi. Symptoms include swelling at the injection site, fever, fatigue, body aches, loss of appetite, nausea, diarrhea or vomiting and swollen glands. Treatment includes antiparasitic medications.
The Chagas Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chagas Disease (American Trypanosomiasis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 4 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 17 and 4 molecules, respectively.
Chagas Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Chagas Disease (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Chagas Disease (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Chagas Disease (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Chagas Disease (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Chagas Disease (Infectious Disease)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Chagas Disease (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Chagas Disease (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Browse Full Report with TOC @ http://www.marketresearchhub.com/report/chagas-disease-pipeline-review-h1-2017-report.html
Table of Contents:
List of Tables
List of Figures
Global Markets Direct Report Coverage
Chagas Disease (American Trypanosomiasis) – Overview
Chagas Disease (American Trypanosomiasis) – Therapeutics Development
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chagas Disease (American Trypanosomiasis) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chagas Disease (American Trypanosomiasis) – Companies Involved in Therapeutics Development
Daiichi Sankyo Company Ltd
Eisai Co Ltd
Grupo Praxis Pharmaceutical SA
KaloBios Pharmaceuticals Inc
Oblita Therapeutics BVBA
Chagas Disease (American Trypanosomiasis) – Drug Profiles
benznidazole – Drug Profile
About Market Research Hub:
Market Research Hub (MRH) is a next-generation reseller of Pharmaceutical Research Reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
90 State Street,
Albany, NY 12207,
Toll Free: 866-997-4948 (US-Canada)